- Home
- AEON vs GNPX Comparison
AEON vs GNPX Comparison
Compare AEON & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- GNPX
- Stock Information
- Founded
- AEON N/A
- GNPX 2009
- Country
- AEON United States
- GNPX United States
- Employees
- AEON N/A
- GNPX N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- AEON Health Care
- GNPX Health Care
- Exchange
- AEON Nasdaq
- GNPX Nasdaq
- Market Cap
- AEON 8.0M
- GNPX 6.6M
- IPO Year
- AEON N/A
- GNPX 2018
- Fundamental
- Price
- AEON $0.81
- GNPX $0.31
- Analyst Decision
- AEON Strong Buy
- GNPX
- Analyst Count
- AEON 1
- GNPX 0
- Target Price
- AEON $360.00
- GNPX N/A
- AVG Volume (30 Days)
- AEON 213.7K
- GNPX 3.5M
- Earning Date
- AEON 08-11-2025
- GNPX 08-08-2025
- Dividend Yield
- AEON N/A
- GNPX N/A
- EPS Growth
- AEON N/A
- GNPX N/A
- EPS
- AEON 117.22
- GNPX N/A
- Revenue
- AEON N/A
- GNPX N/A
- Revenue This Year
- AEON N/A
- GNPX N/A
- Revenue Next Year
- AEON N/A
- GNPX N/A
- P/E Ratio
- AEON $0.01
- GNPX N/A
- Revenue Growth
- AEON N/A
- GNPX N/A
- 52 Week Low
- AEON $0.38
- GNPX $0.20
- 52 Week High
- AEON $269.28
- GNPX $3.97
- Technical
- Relative Strength Index (RSI)
- AEON 56.89
- GNPX 54.54
- Support Level
- AEON $0.80
- GNPX $0.27
- Resistance Level
- AEON $0.87
- GNPX $0.32
- Average True Range (ATR)
- AEON 0.06
- GNPX 0.02
- MACD
- AEON -0.00
- GNPX 0.01
- Stochastic Oscillator
- AEON 61.23
- GNPX 73.00
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.